Press Releases EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Real-time Estimate Cboe BZX Other stock markets 15:51:03 2024-05-03 EDT			5-day change	1st Jan Change
19.78 ^USD	-0.83%		+18.57%	-14.06%

04-02	EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	CI
03-18	EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	04-17	AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	04-16	AQ
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	04-02	AQ
EyePoint Pharmaceuticals : Investor Presentation March 2024	03-22	PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03-18	AQ
EyePoint Pharmaceuticals: Q4 Earnings Snapshot	03-07	AQ
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	03-07	AQ
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	03-04	AQ
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	02-29	AQ
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences	02-27	AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	02-16	AQ
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	02-05	AQ
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	02-03	AQ
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01-31	AQ
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	01-17	AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	01-16	AQ
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema	01-10	AQ
EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	12-20	AQ
EyePoint Pharmaceuticals : EYPT Investor Presentation December 2023	12-19	PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	12-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Press Releases

Filters